本季度信息
根据最新公告，绿竹生物-B在2026年上半年取得其他收入约676.20万元（人民币，下同），同比增长39.4%。公司同期经非公认会计准则口径测算的净亏损约6,162.20万元，与去年同期相比下降20.6%，亏损幅度有所收窄。
公告显示，绿竹生物-B在本期行政开支约2,828.90万元，同比增长9.6%；研发费用约3,033.10万元，同比降低39.7%。公司表示，研发投入的变化主要系在研产品处于不同临床阶段导向所致。经营活动所用现金净额为4,560.80万元，相较于上年同期的7,528.50万元有所改善。
业务分项
公告指出，公司核心产品仍处于新型疫苗和双特异性抗体在研开发阶段，尚未达成规模化盈利。本期其他收入的主要来源包括部分免疫检测试剂盒销售及政府补助。随着项目逐步进入后续临床研发及商业化筹备阶段，公司预计研发与行政开支仍会在合理区间内增长。
高管解读
（无披露相关高管发言，文本不再另行说明。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.